offline
Adial Pharmaceuticals, Inc. (ADIL) is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (''AUD'').
Adial announced that it has established a Scientific Advisory Board (SAB) and has appointed Dr. Giovanni Addolorato, a leading global expert in the field of alcohol use disorder (AUD), as its first member and Chairperson. The SAB will help to guide the Company's strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019.
Shares were briefly halted this morning and upon trading, reached highs of $3.39 before 11AM.
https://finance.yahoo.com/news/healthcar...ccounter=1
ADIL in der spitze von 1.38 auf 4.26, zum schluss 107% im plus bei 2.74
![[Bild: ADILc1dl1603.png]](https://finviz.com/publish/112918/ADILc1dl1603.png)
Adial announced that it has established a Scientific Advisory Board (SAB) and has appointed Dr. Giovanni Addolorato, a leading global expert in the field of alcohol use disorder (AUD), as its first member and Chairperson. The SAB will help to guide the Company's strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019.
Shares were briefly halted this morning and upon trading, reached highs of $3.39 before 11AM.
https://finance.yahoo.com/news/healthcar...ccounter=1
ADIL in der spitze von 1.38 auf 4.26, zum schluss 107% im plus bei 2.74
